We advised Rappta Therapeutics, a private biotech company, in venture capital Series A financing in which the company raised 9 million euros in funding for the development of anti-cancer Protein Phosphatase 2A (PP2A) drugs. The unique phosphatase technology platform offers a new paradigm in oncology.
Novartis Venture Fund, Novo Holdings, Advent Life Sciences and a family office participated in the financing round as investors.
‘We are very pleased to attract such a strong syndicate of international investors, which validates our approach to developing novel therapies to target the previously undruggable target protein PP2A. This funding will enable us to accelerate the development of our platform and advance the lead compounds towards clinical development’, Rappta Therapeutics’s CEO Mikko Mannerkoski said.
Rappta Therapeutics, a private biotech with operations in Finland and the US, is developing first-in-class anti-cancer drugs activating protein phosphatase 2A.
